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Abstract
: Every year, approximately 470,000 new cases of cervical cancer are diagnosed and approximately
230,000 women worldwide die of the disease, with the majority (~80%) of these cases and deaths
occurring in developing countries. Human papillomaviruses (HPVs) are the etiological agents in
nearly all cases (99.7%) of cervical cancer, and the HPV E6 protein is one of two viral oncoproteins
that is expressed in virtually all HPV-positive cancers. E6 hijacks a cellular ubiquitin ligase, E6AP,
resulting in the ubiquitylation and degradation of the p53 tumor suppressor, as well as several other
cellular proteins. While the recent introduction of prophylactic vaccines against specific HPV types
offers great promise for prevention of cervical cancer, there remains a need for therapeutics.
Biochemical characterization of E6 and E6AP has suggested approaches for interfering with the
activities of these proteins that could be useful for this purpose.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Protein pathway involvement in disease
Background
Human papillomaviruses (HPVs) are small DNA tumor
viruses that infect cutaneous or mucosal epithelial cells,
causing papillomas or warts on skin, genital tissues and
the upper promyelocytic leukemia respiratory tract [1].
More than a hundred different HPV types have been char-
acterized, and approximately a third of these infect the
genital tract [2]. The genital HPV types are sexually trans-
mitted and can be further divided into low-risk and high-
risk groups according to the propensity of their induced
lesions to progress to malignancy. The low-risk HPV types,
such as types 6 and 11, are associated with genital warts
that do not progress toward cancer, while the high-risk
HPV types cause intraepithelial lesions that can progress
to invasive carcinomas [3]. High-risk HPV types are asso-
ciated with 99.7% of cervical cancers [4,5]. Specifically,
HPV16 and HPV18 are the high-risk types most frequently
associated with cervical squamous cell carcinomas (50%
and 20%, respectively). The introduction of prophylactic
vaccines against specific HPV types offers great promise
for prevention of these cancers [6]. High-risk HPV types
are also associated with approximately 25% of head and
neck carcinomas (of the mouth, tonsils, esophagus and
larynx, in particular) [7,8].
The HPV E6 and E7 proteins are the only two viral genes
expressed in virtually all HPV-positive cervical carcino-
mas, and many lines of experiments have shown that
these are cooperative viral oncoproteins (reviewed in [9]).
The activities of E6 and E7 that are most clearly linked to
carcinogenesis are their abilities to inactivate the p53 and
the retinoblastoma (pRb) tumor suppressors, respectively.
High-risk HPV E6 proteins bind directly to E6AP, a cellu-
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lar ubiquitin ligase encoded by the UBE3A gene, causing
its substrate specificity to be altered so that it stably asso-
ciates with and polyubiquitylates p53, resulting in degra-
dation of p53 by the 26S proteasome [10,11]. Therefore,
E6 acts (at least in part) as an oncoprotein by stimulating
the destruction of perhaps the most important tumor sup-
pressor proteins in human cancer. The E7 protein also
promotes the proteasome-dependent degradation of pRb
and p130 [12,13]. While the mechanism remains unchar-
acterized, it does not appear to involve E6AP.
It is clear that high-risk HPV E6 proteins have additional,
p53-independent functions, some of which could be
related to cellular immortalization or transformation. For
example, expression of HPV16 E6 in the skin of transgenic
mice induces malignant skin tumors, and this is inde-
pendent of p53 genotype [14]. E6 also induces telomerase
activity [15,16], which is generally associated with cancer-
derived cells. E6-induced telomerase activation requires
E6AP, as demonstrated by the loss of telomerase activity
following siRNA knockdown of E6AP [17,18]. This is due
to targeting of a transcriptional repressor of TERT gene
expression, NFX1-91, by the E6/E6AP complex [18]. Sev-
eral other proteins are targeted by the E6/E6AP complex in
vitro and in vivo, including an array of PDZ domain pro-
teins [19-23], E6TP1 [24,25], MCM7 [26] and Bak [27]
(Figure 1). While the ability of E6 to bind to PDZ domain
proteins is correlated with the ability of the latter to
induce epithelial hyperplasia when expressed in mouse
epidermis [28], it is unclear which specific PDZ domain
proteins are relevant to this activity. Finally, gene expres-
sion profiling of HPV-positive cell lines revealed that the
global effects of knocking-down E6 expression by siRNAs
were nearly identical to the effects of knocking-down
E6AP expression, again suggesting that the complete range
of E6 functions could be dependent on E6AP [17]. It
should also be noted that high-risk HPVs have also been
associated with head and neck cancers, particularly tonsil-
lar carcinoma [29].
The HPV E6 and E6AP proteins
The first in vitro experiments demonstrating the associa-
tion of E6 with p53 and E6-induced ubiquitylation of p53
were performed in a rabbit reticulocyte lystate translation
system [11,30]. Subsequent experiments showed that, in
addition to ubiquitin, E1 and E2 enzymes, rabbit reticulo-
cyte contributed a factor that was required for both stable
association of E6 with p53 and p53 ubiquitylation [31].
This factor was eventually identified as E6AP [32], and by
several criteria, E6AP was defined as an E3 enzyme of the
ubiquitin system [10]. Primary sequence analysis of E6AP
revealed an approximately 350 amino acid C-terminal
domain, now known as the HECT (homologous to E6AP
carboxyl-terminus) domain, which defines a large family
of ubiquitin ligases [33]. There are approximately 50
HECT E3s in humans and five in Saccharomyces cerevisiae,
and they appear to be present in all eukaryotes. The HECT
E3s are unique when compared with all other known
classes of E3s [34] in that, like the E1 and E2 enzymes of
the ubiquitin system, they also have an active-site cysteine
(within the HECT domain) that forms a ubiquitin
thioester intermediate during their reaction cycle [35].
X-ray crystal structures of the HECT domain of three dif-
ferent HECT E3s (E6AP, WWP1 and Smurf2) are now
available [36-38]. The domain consists of a large N-termi-
nal lobe (approximately 250 amino acids) and, connected
by a short flexible hinge, a C-terminal lobe of approxi-
mately 100 amino acids, which contains the active-site
cysteine (Figure 2). The E6AP-UbcH7 structure (2.6 Å res-
Structural and functional domains of E6AP and E6 Figure 1
Structural and functional domains of E6AP and E6. The schematic of E6AP (also known as UBE3A) indicates the loca-
tion of the E6 binding site (E6 BS) and the catalytic HECT domain. The two zinc binding domains and the C-terminal PDZ bind-
ing epitope of HPV16 E6 are indicated. Some of the targets that are inactivated by the E6/E6AP complex are indicated.BMC Biochemistry 2008, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2091/9/S1/S4
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olution) revealed the basis for interaction of the HECT
domain with the activating E2 protein, which docks onto
a surface of the N-terminal lobe [38]. The affinity of the E2
for the HECT domain is quite low (approximately 6 μM)
[39], but this appears to be advantageous for release of the
E2 so that it can be re-charged following transfer of ubiq-
uitin to the HECT active site [39]. Binding and release
appears to be required for catalysis of polyubiquitylation
since the surface of the E2 that interacts with the HECT
domain is predicted to overlap with the surface that inter-
acts with the E1 enzyme.
The most puzzling aspect of the E6AP-UbcH7 structure
was the large distance separating the active-site cysteines
of the two proteins; approximately 41 Å [38]. This dis-
tance obviously precludes a direct transthiolation reaction
without a large conformational rearrangement. It was
therefore interesting to observe that in the WWP1 struc-
ture [37], the active sites were predicted to be approxi-
mately 16 Å apart (after modeling in the E2 structure
based on the E6AP-UbcH7 structure). This difference was
due largely to a conformational change at the hinge con-
necting the N- and C-terminal lobes. In the Smurf2 struc-
ture, the cysteines were predicted to be even further
separated than in the E6AP structure (50 Å) [36]. These
alternative structures have led to the hypothesis that con-
formational changes about the flexible hinge accompany
the transthiolation and substrate ubiquitylation reactions,
with the three known structures perhaps representing
intermediates that each of these proteins might pass
through during the reaction cycle. It appears unlikely that
E2 binding initiates the conformational changes, since the
conformation of E6AP was essentially identical with or
without UbcH7 [38]. Also unresolved is the mechanism
of polyubiquitylation and the basis for synthesis of differ-
ent chain types (e.g. Lys48 versus Lys63 polyubiquityla-
tion). For example, E6AP has a strong preference for
assembly of Lys48-linked polyubiquitin chains, while S.
cerevisiae  Rsp5 has a strong preference for assembly of
Lys63-linked chains [40,41]. Given the very different out-
comes of Lys48 and Lys63 polyubiquitylation [42], it is
important to determine the mechanistic distinction
between Lys48- and Lys63-specific HECT E3s.
The HECT domain, by itself, contains all the determinants
necessary for formation of a ubiquitin thioester interme-
diate [43,44], suggesting that it is a self-contained catalytic
domain. Since all HECT E3s are large proteins (ranging in
size from 92 to over 500 kDa), it has been proposed that
the divergent sequences upstream of the HECT domain
contain the determinants of substrate specificity [33]. This
model is supported by characterization of the E6/E6AP
complex, where the E6 binding domain is localized to an
18 amino acid alpha helical epitope in the central portion
of the protein, centered approximately 120 amino acids
upstream of the HECT domain [32,45,46]. Deletion or
specific point mutations within this helix completely
abrogate both E6 and p53 association, and ubiquitylation
of p53 in vitro [47]. Consistent with this 'two domain'
model, whereby substrates are recognized by N-terminal
epitopes and ubiquitylated by the C-terminal HECT
domain, the WW domains found in the central region of
a subgroup of HECT E3s (e.g. yeast Rsp5 and human
WWP1 and Nedd4) have been shown in many cases to be
the primary determinants of substrate specificity of these
enzymes (reviewed in [48]). Structure-function relation-
ships of E6AP and E6 are summarized in Figure 1.
Based on the notion that E6 redirects the substrate specif-
icity of E6AP, a simple model is that E6 binds to both
E6AP and p53, bridging the interaction between enzyme
and substrate. However, while E6 binds directly to E6AP,
in vitro binding assays indicate that neither E6 nor E6AP
interacts significantly with p53 in the absence of the other
[32]. This suggests that either the two proteins together
form a surface for p53 interaction, or that one of these
proteins influences the conformation of the other so that
it can interact with p53. It should be noted that there have
been reports that E6 does bind directly to p53 in the
absence of E6AP [49], however the significance of this
interaction is contentious [50]. In this context, the basis
for variable findings could be due to the problems in
expressing purified soluble E6 protein for biochemical
experiments. The bridging model clearly applies to the
The X-ray crystal structure of the complex of the E6AP  HECT domain with UbcH7 (PDB 1DF5) Figure 2
The X-ray crystal structure of the complex of the 
E6AP HECT domain with UbcH7 (PDB 1DF5). The 
HECT N lobe (blue), linker (red) and C lobe (green) are indi-
cated. UbcH7 (magenta) was co-crystallized with the HECT 
domain, while ubiquitin (black) is modeled into the structure 
shown based on a Ubc1-ubiquitin model [72] (PDB 1FXT). 
The dashed line represents the 41 Å line-of-site between the 
active-site cysteines of UbcH7 and E6AP. Adapted from [38].BMC Biochemistry 2008, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2091/9/S1/S4
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interaction of the E6/E6AP complex with its PDZ domain
protein targets. E6 is able to bind directly to these target
proteins, both independently of E6AP as well as simulta-
neously to both PDZ domain proteins and E6AP [22]. The
interaction between E6 and PDZ domain proteins is
mediated by a conserved C-terminal PDZ binding epitope
(consisting of S/T-x-V/L). Interestingly, all of the high-risk
cancer-associated HPV E6 proteins contain a consensus
PDZ binding epitope that is absent in all other papilloma-
virus E6 proteins. While this is compelling circumstantial
evidence that targeting of PDZ proteins could play a role
in carcinogenesis, this has not yet been directly demon-
strated.
The E6 proteins have been very difficult to analyze struc-
turally, even though they are only 150–160 amino acids
in length. This is due to aggregation when they are
expressed in significant amounts [51]. All E6 proteins con-
tain two zinc binding domains, each consisting of a C-X-
X-C-X29-C-X-X-C sequence (Figure 1). An NMR structure
of the C-terminal zinc binding domain of HPV16 E6 was
recently solved and a model of the full-length protein was
proposed, suggesting that E6 proteins consist of a con-
served structural scaffold with highly variable surfaces par-
ticipating in specialized HPV functions [52]. While many
studies have characterized E6 mutants with respect to E6
and p53 association, there is no structural information
that indicates which surface of E6 interacts with either
E6AP or p53.
In summary, the interaction of E6 with E6AP directs the
ubiquitylation activity of E6AP toward several specific cel-
lular proteins, the most notable of which with respect to
carcinogenesis is p53. Surprisingly, very few of the natural
(i.e. E6-independent) targets of E6AP have been identi-
fied. This is a very important problem, since mutations or
disruption in expression of E6AP in the brain are the cause
of Angelman syndrome (AS), a severe form of mental
retardation [53-55]. Though E6AP is expressed in virtually
all cells of the human body, in subregions of the brain
(including the hippocampal neurons and Purkinje cells)
E6AP is expressed only from the maternal allele. AS is
caused by disruptions in expression of the maternal allele
of E6AP, generally by large chromosomal deletion but
also by point mutations within the E6AP coding
sequence. This strongly suggests that lack of ubiquityla-
tion of one or more E6AP target proteins in the brain is
responsible for the severe AS phenotype.
Disease models, knockouts, assays
While the discovery of the Shope cottontail rabbit papil-
lomavirus (CRPV) was one of the earliest descriptions of
an animal DNA tumor virus [56], there are no animal
models for cervical carcinogenesis involving the high-risk
HPVs. Moreover, though a rhesus monkey sexually trans-
mitted papillomavirus has been associated with malig-
nancies [57], it has not been established that the E6
protein of this virus (RhPV-1) targets p53 for degradation
or interacts with E6AP. RhPV-1 E6 clusters with the high-
risk HPV E6 proteins based on sequence similarity,
although it lacks their characteristic PDZ binding epitope.
The laboratory of Paul Lambert (University of Wisconsin)
developed an E6 transgenic mouse model that has been
very useful in dissecting the functions of E6 in a multi-step
model of skin cancer [14]. Transgenic mice expressing a
mutant of E6 defective for E6AP interaction showed mark-
edly reduced phenotypes associated with E6 expression,
including the development of spontaneous skin tumors
[58]. In addition, the PDZ binding activity of E6 was
found to contribute to the progression stage of carcino-
genesis in this model, but not to the promotion stage [59].
The PDZ binding activity was also important for the abil-
ity of E6 to induce epithelial hyperplasia when expressed
in the eye [28]. Therefore, the transgenic mouse system,
combined with the knowledge from biochemical charac-
terization of E6 and E6AP, has proven to be a useful tool
for dissecting the contribution of various E6 activities to
carcinogenesis.
The productive replication cycle of papillomaviruses is
notoriously difficult to study given the tight linkage of
virus transcription and replication to the differentiation
program of the infected epithelial tissue. The most useful
system for studying this in the laboratory has been the
organotypic raft culture system, where cultured primary
keratinocytes can be induced to differentiate at the air-liq-
uid interface. Laimins and colleagues (Northwestern Uni-
versity) have shown that, in this context, cells that contain
HPV DNA will yield infectious papillomavirus particles
[60]. By introducing specific mutations into different viral
ORFs, this system allows some very basic questions to be
addressed [60,61]. In this system, deletion of the PDZ
binding domain of HPV31 E6 had relatively little effect on
virus replication, although there was a slight effect on viral
DNA copy number and early stimulation of proliferation
[62]. The use of cells suspended in semi-solid media
(methylcellulose) is another way in which differentiation
can be recapitulated in a manner that supports viral prop-
agation [63]. The contribution of E6AP to virus replica-
tion has, to our knowledge, not been directly examined in
these systems to date.
Finally, it should be emphasized that several HPV-positive
cell lines derived from cervical cancers or their metastases
are widely available, and these are useful for addressing
certain HPV E6 functions, including targeting of p53. The
best known HPV-containing cell line is HeLa, an HPV18-
containing cell line isolated over 50 years ago from a cer-
vical carcinoma patient [64]. Perhaps surprisingly, evenBMC Biochemistry 2008, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2091/9/S1/S4
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after 50 years in culture, HeLa cells are still dependent on
continued expression of E6 for their survival, as knock-
down of either E6 or E6AP with siRNA results in the rapid
accumulation of p53 [17] and the induction of apoptosis
[65]. Other commonly used HPV cell lines available
include SiHa (HPV16), Caski (HPV16) and C4-I
(HPV18).
Disease targets and ligands
Our knowledge of the molecular details of the interac-
tions between E6 and E6AP, as well as between E6AP and
activating E2 enzymes, present opportunities for interfer-
ing with degradation of p53 in HPV-positive cervical can-
cers or precursor lesions. The NMR structure of the 18
amino acid E6 binding domain of E6AP has been deter-
mined [45]. The leucine residues within this peptide form
a hydrophobic patch on a face of the helix, and mutation
of any of these residues to alanine abolishes E6 binding
[45]. Recently, building on the structural and mutagenesis
information, a three-dimensional query was developed by
Baleja and co-workers (Tufts University School of Medi-
cine) to identify potential small molecule inhibitors of E6
binding [66]. This approach successfully identified com-
pounds that blocked E6 binding and stabilized p53 in E6-
expressing cells. These compounds represent exciting lead
molecules for future development. Other attempts at
inhibiting E6 function include work by Beerheide and co-
workers (Institute of Molecular and Cell Biology, Singa-
pore) identifying compounds that chelate zinc away from
E6 [67,68].
The HECT domain-E2 interaction surface represents
another potential drug target. Since the surface of the E2
that interacts with the HECT domain is involved in inter-
actions with many E3s, as well as with the E1 enzyme, tar-
geting of the surface of the HECT domain could provide
greater specificity. The molecular details of this interaction
are well understood [38,39]. Another route toward inhib-
iting E6AP would be to isolate compounds that block the
large conformational rearrangements that are presumed
to occur during the reaction cycle. The C-terminal tail of
the HECT domain contains a conserved phenylalanine
residue (the -4F, named for its location relative to the C-
terminus), and mutation of this reside blocks protein
ubiquitylation, but not ubiquitin thioester formation
[69]. The tail residues could therefore also be attractive
drug targets for blocking protein ubiquitylation.
New frontiers in drug discovery
The future is certain to see the continued development of
more advanced prophylactic HPV vaccines that target a
wider variety of HPV types, as well as therapeutic HPV vac-
cines. Nevertheless, effective antiviral compounds could
be useful in treatment of pre-existing disease. E6 is an
excellent target because it is expressed through all stages of
carcinogenesis and its mode of action is well character-
ized. In addition, established in vitro assays and cell-based
assays for E6/E6AP-dependent ubiquitylation of p53
present excellent opportunities for isolation of com-
pounds that inhibit specific protein-protein associations
or specific steps in the catalytic cycle.
A concern about any approach aimed at inhibiting E6AP
is that loss-of-function mutations in E6AP/UBE3A cause
AS. The natural, E6-independent targets of E6AP are
poorly characterized, although one interesting target
recently reported is the Rho-GEF Pbl/Ect2, which is regu-
lated by mouse E6AP in neurons [70]. While it is not
known whether targeting of Pbl/Ect2 is related to AS, the
effects of blocking the ubiquitylation of the complete set
of E6-independent targets of E6AP must be considered
during attempts to interfere with E6AP activity in HPV-
induced lesions. This consideration could rule out sys-
temic delivery of anti-E6AP drugs, although the nature of
HPV infections suggests that topical drug application
might, at least in some cases, be a viable delivery route.
Finally, further biochemical and mechanistic studies of
HECT E3s could reveal novel approaches for interfering
with specific aspects of the reaction cycle. For example,
E6AP catalyzes the formation of Lys48-linked polyubiqui-
tin chains, while some other HECT E3s, such as yeast
Rsp5, have a strong preference for catalysis of Lys63-
linked chains [40,41]. Lys48 chains typically target pro-
teins to the proteasome, while it is clear that Lys63-linked
chains can have non-proteolytic functions [71]. Therefore,
inhibition or alteration of the type of polyubiquitin chain
synthesized by E6AP could be a viable target for drug dis-
covery.
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